Indeed, some recent studies have suggested the clinical benefit of nivolumab after RAM, an anti-vascular endothelial growth factor receptor 2 monoclonal antibody, in patients with advanced gastric cancer [14, 15]. The gene discussed is KDR; the disease is gastric cancer.